ClinicalTrials.govpublic full text
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma
non-small cell lung cancer, egfr, nsclc, egfr mutation rate, interventional, na
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 992980
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.